The antibody treatment for COVID-19 made by a South Korean pharmaceutical giant, Celltrion has gone under review.
According to the Ministry of Food and Drug Safety, a COVID-19 vaccine and treatment licensing review team aims to finish the review and to grant approval within 40 days.
This comes as the company applied for the ministry's permission on Tuesday.
Celltrion is the third company in the world to apply for approval for an experimental COVID-19 treatment.
The company has also applied for emergency-use approval in the U.S. and Europe.